Business Wire

CA-VAULTREE

15.3.2023 14:03:33 CET | Business Wire | Press release

Share
Vaultree Launches Software Development Kit, Making Scalable Data-In-Use Encryption Generally Available to All Enterprises

More than 4,100 publicly disclosed data breaches occurred in 2022, with approximately 22 billion records leaked. Most of it was not encrypted. Vaultree, the Data-In-Use Encryption leader, today announced the general availability of a first-of-its-kind software development kit (SDK) to address this massive need.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005361/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vaultree's first-of-its-kind Fully Functional Data-In-Use Encryption toolkit will transform enterprise security. (Graphic: Business Wire)

Made possible by a series of major cryptographic breakthroughs by the Vaultree team, the SDK is a user-friendly, simple-to-integrate, and easy-to-use fully scalable solution that enables organizations to benefit from Fully Functional Data-In-Use Encryption, allowing for the processing of fully encrypted data without server-side decryption and complex intermediaries or noticeable delays in data processing.

Vaultree developed the solution to address the problems associated with processing completely encrypted data at scale, ensuring that companies no longer need to sacrifice security for performance and are able to keep their data safe at all times with unmatched simplicity and exceptional encrypted data processing rates. Businesses can retain their tech stack, database, code and SQL syntax, follow the rules, and operate without any perceptible changes, with the added benefit of being completely encrypted and at scale. Vaultree's SDK provides protection, including adherence, security and effectiveness. So, in the event of a leak, rather than issuing an apology about the wholesale exposure of sensitive data, companies will be able to inform clients that although their data has been compromised, it is encrypted, meaning it is protected by encryption, an unparalleled level of security.

This layer of protection also makes CISOs' lives easier by solving one of the most difficult challenges in cybersecurity: persistent data encryption, even in the event of a leak, with the world's first Fully Functional Data-In-Use Encryption solution. Encryption technologies to date have not been able to process encrypted data, decrypting it to plain text for processing and therefore impacting organizations' overall data security, making their data readily available to cyber criminals. Vaultree's encryption solution is smarter, quicker, easier, and more efficient than anything else on the market. Truly zero-trust, it allows users to work with fully encrypted data without key disclosure or server-side decryption. Data-In-Use Encryption maintains data encrypted at all times, even during processing. As an added benefit, there are no intermediaries, which translates to zero learning curve or implementation overhead, making adoption seamless.

Ease of integration and use is another critical differentiator of Vaultree's SDK encryption solution. There is no need to be a cryptographer, no intermediaries (such as APIs, proxies or plugins), no change of data architecture, and no code or SQL syntax change. This remarkable adaptability has made the product a prime mover in the market.

"Vaultree's groundbreaking solution is the first of its kind and will change the encryption landscape as we know it. Data security is not only one of today's hot topics but also the topic of tomorrow. Vaultree is leading the way to a safer future," said Rinki Sethi, member of Vaultree's executive board of directors.

Vaultree's SDK encryption solution tackles the drawbacks of both conventional and contemporary encryption methods with a variety of features, including:

  • Close to plaintext processing speed, even at scale
  • Keys reside with the client
  • End-to-end encrypted in use, decrypted only client-side
  • No changes to stack, SQL syntax, data structure, architecture, and network topology
  • Complex processing from fulltext search to computations on randomized encrypted data
  • Performance and scalability at enterprise levels
  • No need for special purpose hardware

Peak performance processing on fully encrypted data enables enterprises to scale to billions of datasets while processing data at speeds similar to unencrypted data processing. Enterprises handling large amounts of sensitive data, including those in financial services, healthcare, pharmaceutical, insurance, retail, telecom, and energy sectors, will be able to mitigate the tremendous economic, cyber, legal, reputational, and business risk of a data breach in plain text — because of the data being encrypted.

"Breaches or leaks will continue happening, no matter how many tools are in the first line of defense, but the second line of defense — encryption — has been neglected for decades because data still has to be decrypted to be worked with. The only way forward is an always-encrypted approach," said Tilo Weigandt, Co-Founder and COO of Vaultree.

Amongst other developments, Vaultree is the first and only (Data-In-Use) encryption solution vendor to partner with Google's AlloyDB for PostgreSQL, leading a new era with a fully functional encryption solution in the cloud. To further expand usage of its revolutionary data protection solution, Vaultree has also partnered with Qrypt. The partnership leverages Qrypt’s ability to independently generate identical symmetric keys at multiple endpoints and quantum-secure future-safe one-time pad encryption paired with Vaultree’s Fully Functional Data-In-Use Encryption to enable fast, future secure data processing in a cloud-first world.

"As it stands, we are the only company globally with the capacity and innovation we have. We are going to grow significantly over the next year enabling organizations with our Data-In-Use encryption technology. We are focusing heavily on bringing this to market fast with our target markets being North America and Europe," said Ryan Lasmaili, Co-Founder and CEO of Vaultree.

About Vaultree

Vaultree has developed the world's first Fully Functional Data-in-Use Encryption solution that solves the industry's fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree's data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005361/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye